– Phase 2 study met primary objective, supporting initiation of two parallel Phase 3 studies that will enroll ~370 AL amyloidosis patients – – Positive long-term Phase 1a/1b data presented at the International Symposium on Amyloidosis (ISA) 2020 demonstrate prolonged overall survival (78% at 37 months) and durable organ response […]
Coronary/Structural Heart
VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia
TOTUM-070 exclusivity guaranteed in the United States and in Europe for reducing blood LDL-cholesterol levels, a cardiovascular disease risk factor; Intellectual property rights protecting the composition of the TOTUM-070 active substance for food and pharmaceutical applications; A milestone in the further development of TOTUM-070, in the search for commercial partnerships […]
Venus Medtech Taps into Surgical Heart Valve Market by Cooperating with Haoyue Group to Develop the Business of High-end Biomaterial Medical Devices
HANGZHOU, China, Sept. 10, 2020 /PRNewswire/ — The leading transcatheter heart valve medical device player in China – Venus Medtech (Hangzhou) Inc. (“Venus Medtech” or the “Company”, together with its subsidiaries, the “Group”, stock code: 2500) and Jilin Changchun Haoyue Halal Meat Co., Ltd (“Haoyue Group“), are pleased to announce the establishment of a joint venture company, Venus Haoyue Medtech […]
CHF Solutions’ Physician-Led Webinar Concludes Fluid Overloaded Heart Failure Patients Benefit from Ultrafiltration
EDEN PRAIRIE, Minn., Sept. 10, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced key takeaways from a recent webinar, where Dr. John L. Jefferies discussed the use of precision medicine for the treatment […]
Medtronic Receives Breakthrough Device Designation from FDA, Begins Early Feasibility Study…
Medtronic Receives Breakthrough Device Designation from FDA, Begins Early Feasibility Study for Investigational Intrepid™ Transcatheter Valve System for the Treatment of Tricuspid Valve Regurgitation DUBLIN, Sept. 9, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced U.S. Food and Drug Administration (FDA) approval of an early feasibility […]
AACC and CDC Partner to Improve Cardiovascular Disease Testing Around the World
WASHINGTON, Sept. 9, 2020 /PRNewswire/ — AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce a new collaboration with the Centers for Disease Control and Prevention (CDC) and the CDC Foundation that aims to expand lipid testing in resource-limited countries. Improving access […]
MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy
BRISBANE, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere. Danicamtiv […]
Impulse Dynamics Announces CMS Proposed Rule Would Improve Medicare Coverage of CCM Therapy Delivered by the Optimizer System
Rule would give Medicare patients immediate access to breakthrough heart failure therapy MT. LAUREL, N.J.–(BUSINESS WIRE)–Impulse Dynamics, Inc., a company dedicated to improving the lives of people with heart failure, today announced that a proposed rule by the Centers for Medicare and Medicaid Services (CMS) could further streamline coverage of […]
CeleCor Announces Publication of Positive Clinical Results of RUC-4, a Novel Second Generation Platelet GPIIb/IIIa Inhibitor Designed for Subcutaneous Point-of-Care STEMI Therapy
RUC-4 is the first and only GPIIb/IIIa inhibitor that is in clinical development as a simple, single subcutaneous injection treatment to potently and rapidly block all platelet aggregation pathways to improve outcomes for heart attack patients September 03, 2020 09:00 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–CeleCor Therapeutics, Inc. announced positive […]
CHF Solutions Continues Physician-Led Webinar Series Discussing Precise Management of Fluid Overload in Patients with Acute Heart Failure
EDEN PRAIRIE, Minn., Sept. 03, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the company will host an interactive, physician-led webinar to discuss “Precision Medicine for the Treatment of Fluid Overload in Patients […]



